A drug previously approved for treating migraine and epilepsy has been found to slow the growth of triple negative breast cancer in mouse models. Researchers carried out screening studies to identify known pharmacologically active compounds that trigger degradation of N-Ras, a key protein that drives the development of aggressive basal-like breast cancer.
The post Triple-Negative Breast Cancer in Mice Inhibited by Migraine Drug appeared first on GEN - Genetic Engineering and Biotechnology News.
Original Article: Triple-Negative Breast Cancer in Mice Inhibited by Migraine Drug